At a glance
ClinicalIndex Comparison RecordN/ACompleted· 157 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective Analysis of Clinical Factors Associated With Greater Benefit of Axitinib in Metastatic Renal Cancer (AXILONG Study)
In Brief
An observational study for Carcinoma, Renal Cell. Completed, enrolled 157 participants across 40 sites.
Detailed Summary
Retrospective study to collect data from Patients with advanced/metastatic renal cell carcinoma previously treated with Axitinib under standard clinical practice, to describe the clinical profile of the patients with a long response to Axitinib and to try to identify clinical factors which could be related with the long response to Axitinib, through the comparison between long responder patients and a group of refractory patients
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedMay 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedMay 29, 2018
Enrollment StartApr 19, 2018
Primary CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.1 years ago